Angiopoietin2 enhances doxorubin resistance in HepG2 cells by upregulating survivin and Ref-1 via MSK1 activation

Cancer Letters

Volumn 337, Issue 2, 2013, Pages 276-284

  Li, Tao ^a   Liu, Zhiqiang ^b   Jiang, Kesheng ^a   Ruan, Qin ^a  

^a ZHEJIANG NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiopoietin 2; Apoptosis; CREB; Doxorubicin; HepG2 cells; MSK

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOXORUBICIN; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; REDOX EFFECTOR FACTOR 1; SMALL INTERFERING RNA; SURVIVIN;

ARTICLE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CELL STRAIN HEPG2; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SCREENING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOPOIETIN-2; APOPTOSIS; CREB; DOXORUBICIN; HEPG2 CELLS; MSK;

ANGIOPOIETIN-2; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HISTONES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MITOCHONDRIA; OXIDATIVE STRESS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; RECEPTOR, TIE-2; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA INTERFERENCE; TRANSFECTION; UP-REGULATION;

EID: 84880510067     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.028     Document Type: Article

References (42)

1. Shim W.S., Ho I.A., Wong P.E. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol. Cancer Res. 2007, 5:655-665.
2. Bach F., Uddin F.J., Burke D. Angiopoietins in malignancy. Eur. J. Surg. Oncol. 2007, 33:7-15.
3. Tanaka S., Mori M., Sakamoto Y., Makuuchi M., Sugimachi K., Wands J.R. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J. Clin. Invest. 1999, 103:341-345.
4. Staton C.A., Hoh L., Baldwin A., Shaw L., Globe J., Cross S.S., Reed M.W., Brown N.J. Angiopoietins 1 and 2 and Tie-2 receptor expression in human ductal breast diseasem. Histopathology 2011, 59:256-263.
5. Schulz P., Fischer C., Detjen K.M., Rieke S., Hilfenhaus G., von Marschall Z., Bohmig M., Koch I., Kehrberger J., Hauff P., Thierauch K.H., Alves F., Wiedenmann B., Scholz A. Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. Faseb J. 2011, 25:3325-3335.
6. Saito M., Watanabe J., Fujisawa T., Kamata Y., Nishimura Y., Arai T., Miyamoto T., Obokata A., Kuramoto H. Angiopoietin-1, 2 and Tie2 expressions in endometrial adenocarcinoma - the Ang2 dominant balance up-regulates tumor angiogenesis in the presence of VEGF. Eur. J. Gynaecol. Oncol. 2006, 27:129-134.
7. Quentin T., Schlott T., Korabiowska M., Kathei N., Zoller G., Glaser F., Kunze E. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res. 2004, 24:2745-2756.
8. Etoh T., Inoue H., Tanaka S., Barnard G.F., Kitano S., Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001, 61:2145-2153.
9. Durkin A.J., Bloomston M., Yeatman T.J., Gilbert-Barness E., Cojita D., Rosemurgy A.S., Zervos E.E. Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumors. J. Am. Coll. Surg. 2004, 199:724-731.
10. Detjen K.M., Rieke S., Deters A., Schulz P., Rexin A., Vollmer S., Hauff P., Wiedenmann B., Pavel M., Scholz A. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin. Cancer Res. 2010, 16:420-429.
11. Srirajaskanthan R., Dancey G., Hackshaw A., Luong T., Caplin M.E., Meyer T. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocr. Relat. Cancer 2009, 16:967-976.
12. Scholz A., Rehm V.A., Rieke S., Derkow K., Schulz P., Neumann K., Koch I., Pascu M., Wiedenmann B., Berg T., Schott E. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am. J. Gastroenterol. 2007, 102:2471-2481.
13. Huang H., Lai J.Y., Do J., Liu D., Li L., Del Rosario J., Doppalapudi V.R., Pirie-Shepherd S., Levin N., Bradshaw C., Woodnutt G., Lappe R., Bhat A. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin. Cancer Res. 2011, 17:1001-1011.
14. Mazzieri R., Pucci F., Moi D., Zonari E., Ranghetti A., Berti A., Politi L.S., Gentner B., Brown J.L., Naldini L., De Palma M. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
15. Morrissey C., Dowell A., Koreckij T.D., Nguyen H., Lakely B., Fanslow W.C., True L.D., Corey E., Vessella R.L. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 2010, 70:1799-1808.
16. Nealand J., Wakelee H. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr. Opin. Mol. Ther. 2010, 12:487-495.
17. Holopainen T., Saharinen P., D'Amico G., Lampinen A., Eklund L., Sormunen R., Anisimov A., Zarkada G., Lohela M., Helotera H., Tammela T., Benjamin L.E., Yla-Herttuala S., Leow C.C., Koh G.Y., Alitalo K. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J. Natl. Cancer Inst. 2012, 104:461-475.
18. Leow C.C., Coffman K., Inigo I., Breen S., Czapiga M., Soukharev S., Gingles N., Peterson N., Fazenbaker C., Woods R., Jallal B., Ricketts S.A., Lavallee T., Coats S., Chang Y. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int. J. Oncol. 2012, 40:1321-1330.
19. Hashizume H., Falcon B.L., Kuroda T., Baluk P., Coxon A., Yu D., Bready J.V., Oliner J.D., McDonald D.M. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010, 70:2213-2223.
20. Coxon A., Bready J., Min H., Kaufman S., Leal J., Yu D., Lee T.A., Sun J.R., Estrada J., Bolon B., McCabe J., Wang L., Rex K., Caenepeel S., Hughes P., Cordover D., Kim H., Han S.J., Michaels M.L., Hsu E., Shimamoto G., Cattley R., Hurh E., Nguyen L., Wang S.X., Ndifor A., Hayward I.J., Falcon B.L., McDonald D.M., Li L., Boone T., Kendall R., Radinsky R., Oliner J.D. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol. Cancer Ther. 2010, 9:2641-2651.
21. Falcon B.L., Hashizume H., Koumoutsakos P., Chou J., Bready J.V., Coxon A., Oliner J.D., McDonald D.M. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol. 2009, 175:2159-2170.
22. Imanishi Y., Hu B., Xiao G., Yao X., Cheng S.Y. Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway. J. Biol. Chem. 2011, 286:29249-29260.
23. Takenaga K. Angiogenic signaling aberrantly induced by tumor hypoxia. Front. Biosci. 2011, 16:31-48.
24. Huand B., Cheng S.Y. Angiopoietin-2: development of inhibitors for cancer therapy. Curr. Oncol. Rep. 2009, 11:111-116.
25. Reber L., Vermeulen L., Haegeman G., Frossard N. Ser276 phosphorylation of NF-kB p65 by MSK1 controls SCF expression in inflammation. PLoS ONE 2009, 4:e4393.
26. Merluzzi S., D'Orlando O., Leonardi A., Vitale G., Pucillo C. TRAF2 and p38 are involved in B cells CD40-mediated APE/Ref-1 nuclear translocation: a novel pathway in B cell activation. Mol. Immunol. 2008, 45:76-86.
27. Li T., Liu Z., Hu X., Ma K., Zhou C. Involvement of ERK-RSK cascade in phenylephrine-induced phosphorylation of GATA4. Biochim. Biophys. Acta 1823, 2012:582-592.
28. Haugeand C., Frodin M. RSK and MSK in MAP kinase signalling. J. Cell Sci. 2006, 119:3021-3023.
29. Vermeulen L., Vanden Berghe W., Beck I.M., De Bosscher K., Haegeman G. The versatile role of MSKs in transcriptional regulation. Trends Biochem. Sci. 2009, 34:311-318.
30. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 2000, 275:10761-10766.
31. Groschand S., Kaina B. Transcriptional activation of apurinic/apyrimidinic endonuclease (Ape, Ref-1) by oxidative stress requires CREB. Biochem. Biophys. Res. Commun. 1999, 261:859-863.
32. Yang J.L., Tadokoro T., Keijzers G., Mattson M.P., Bohr V.A. Neurons efficiently repair glutamate-induced oxidative DNA damage by a process involving CREB-mediated up-regulation of apurinic endonuclease 1. J. Biol. Chem. 2010, 285:28191-28199.
33. Wong J.C., Bathina M., Fiscus R.R. Cyclic GMP/protein kinase G type-Ialpha (PKG-Ialpha) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Ialpha kinase activity synergizes with cisplatin in non-small cell lung cancer cells. J. Cell. Biochem. 2012, 113:3587-3598.
34. Wilson T.R., Johnston P.G., Longley D.B. Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets 2009, 9:307-319.
35. Schimmerand A.D., Dalili S. Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematol. Am. Soc. Hematol. Educ. Program 2005, 215-219.
36. Dohi T., Beltrami E., Wall N.R., Plescia J., Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 2004, 114:1117-1127.
37. Zhangand Y., Wang J. Anticancer clinical utility of the apurinic/apyrimidinic endonuclease/redox factor-1 (APE/Ref-1). Chin. J. Cancer 2010, 29:333-339.
38. Kelley M.R., Georgiadis M.M., Fishel M.L. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr. Mol. Pharmacol. 2012, 5:36-53.
39. Raffoul J.J., Heydari A.R., Hillman G.G. DNA repair and cancer therapy: targeting APE1/Ref-1 using dietary agents. J. Oncol. 2012, 2012:370481.
40. Modok S., Mellor H.R., Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol. 2006, 6:350-354.
41. Imanishi Y., Hu B., Jarzynka M.J., Guo P., Elishaev E., Bar-Joseph I., Cheng S.Y. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res. 2007, 67:4254-4263.
42. Scholz A., Lang V., Henschler R., Czabanka M., Vajkoczy P., Chavakis E., Drynski J., Harter P.N., Mittelbronn M., Dumont D.J., Plate K.H., Reiss Y. Angiopoietin-2 promotes myeloid cell infiltration in a beta(2)-integrin-dependent manner. Blood 2011, 118:5050-5059.